0001209191-23-059268.txt : 20231219 0001209191-23-059268.hdr.sgml : 20231219 20231219194430 ACCESSION NUMBER: 0001209191-23-059268 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221009 FILED AS OF DATE: 20231219 DATE AS OF CHANGE: 20231219 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lim Seah H. CENTRAL INDEX KEY: 0001949484 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35527 FILM NUMBER: 231499026 MAIL ADDRESS: STREET 1: 21250 HAWTHORNE BLVD. STREET 2: SUITE 800 CITY: TORRANCE STATE: CA ZIP: 90503 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Emmaus Life Sciences, Inc. CENTRAL INDEX KEY: 0000822370 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 870419387 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 21250 HAWTHORNE BOULEVARD, SUITE 800 CITY: TORRANCE STATE: CA ZIP: 90503 BUSINESS PHONE: 310-214-0065 MAIL ADDRESS: STREET 1: 21250 HAWTHORNE BOULEVARD, SUITE 800 CITY: TORRANCE STATE: CA ZIP: 90503 FORMER COMPANY: FORMER CONFORMED NAME: MYnd Analytics, Inc. DATE OF NAME CHANGE: 20151211 FORMER COMPANY: FORMER CONFORMED NAME: CNS RESPONSE, INC. DATE OF NAME CHANGE: 20070313 FORMER COMPANY: FORMER CONFORMED NAME: STRATIVATION, INC. DATE OF NAME CHANGE: 20051115 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2022-10-09 0 0000822370 Emmaus Life Sciences, Inc. EMMA 0001949484 Lim Seah H. 21250 HAWTHORNE BLVD. SUITE 800 TORRANCE CA 90503 1 0 0 0 0 Common stock, $0.001 par value 2022-10-09 4 P 0 25400 0.11 A 63900 D Common stock, $0.001 par value 2023-08-25 4 P 0 92100 0.27 A 156000 D Common stock, $0.001 par value 2023-08-30 4 P 0 20000 0.15 A 176000 D Common stock, $0.001 par value 2023-09-05 4 P 0 1700 0.15 A 177700 D Common stock, $0.001 par value 2023-12-15 4 S 0 6000 0.11 D 171700 D Common stock, $0.001 par value 2023-12-15 4 J 0 4447426 0.29 A 4619126 D Promissory Note due 9/16/2025 0.29 2023-12-15 4 J 0 240000 D Common Stock 240000 0 D The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.20 to $0.27, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1). The shares shown were issued in exchange for principal and accrued interest under the promissory note of the Issuer held by the reporting person referred to in footnote (2), below, which promissory note was surrendered by the reporting person for cancellation. Promissory Note due 9/16/2025 surrendered for cancellation in exchange for shares of common stock referred to in footnote (1) above. Represent shares previously issuable upon maturity of the Promissory Note due 9/16/2025. Seah H. Lim 2023-12-19